The Democrat Party has spent years demanding transparency, accountability, and the sanctity of elections from its political opponents. It has prosecuted those arguments with relentless fervor — right up until the moment those same standards were applied to its own fundraising apparatus. Now, ActBlue, the left’s premier small-dollar donation engine, stands accused of misleading Congress about its ability to keep foreign money out of American elections, and three of the most powerful committee chairmen in the House are running out of patience.
On Tuesday, House Administration Committee Chairman Bryan Steil (R-WI), House Judiciary Committee Chairman Jim Jordan (R-OH), and House Oversight Committee Chairman James Comer (R-KY) sent a formal letter to ActBlue CEO Regina Wallace-Jones demanding documents the organization has resisted handing over despite a standing subpoena. The letter gives ActBlue two weeks — until April 28 — to comply, warning that Congress is “prepared to use available mechanisms to enforce our subpoenas” if the organization continues to stonewall.
The stakes here are not merely procedural. This is a story about whether one of the most consequential financial pipelines in American political history was built on a foundation of legal fiction.
What ActBlue Told Congress — and What Its Lawyers Feared
In November 2023, facing growing Republican scrutiny, Wallace-Jones wrote to the House Administration Committee assuring lawmakers that ActBlue’s compliance measures were exhaustive.
“Our approach is multilayered, with checks and confirmations occurring throughout the donation process to verify donors and donor information. These measures, which include compliance measures, technological tools, and manual reviews, help to ensure the identity of donors, root out potential foreign contributions, and protect donors from financial fraud.”
Those were reassuring words. The problem is that ActBlue’s own lawyers at Covington & Burling apparently did not believe them. According to internal memos first reported by the New York Times, the law firm warned that Wallace-Jones’ letter presented “an overly optimistic version” of the organization’s actual donation-screening capabilities. The memos noted that donors using third-party apps — Apple Pay, PayPal, Venmo — were not, in practice, being asked to submit U.S. passport information as the letter implied. The firm warned of “a substantial risk that some of the funds received were impermissible contributions from foreign nationals.”
The legal analysis did not stop there. Covington specifically outlined the “potential legal risks associated with statements to Congress that may be alleged to be false or misleading,” noting that an aggressive prosecutor could view Wallace-Jones’ 2023 letter not merely as an inaccuracy, but as an active effort to conceal illegal contributions. Under federal law, lying to Congress carries penalties of up to five years in prison and $250,000 in fines. More significantly, if the violations were deemed “knowing and willful,” the Justice Department would have direct criminal jurisdiction.
The Exodus Nobody Wanted to Talk About
What followed the Covington memos was not a quiet internal review. It was, by most accounts, an organizational meltdown. The legal warnings reportedly triggered panic at the highest levels of ActBlue, leading to a wave of resignations across the company’s legal department — including the entire general counsel’s office. ActBlue also severed its relationship with Covington & Burling entirely in March 2025. Wallace-Jones later blamed the split on “more than a year of navigating tardiness, unpreparedness, and counsel that borders” on inadequacy — a characterization that conveniently shifts the narrative away from the substance of what those lawyers actually said.
Republicans are now demanding two specific documents from that turbulent period. The first is the resignation letter of former General Counsel Aaron Ting, which they believe centers on liabilities created by ActBlue’s donation security practices. The second is a communication from former legal counsel Zain Ahmad relating to what Republicans describe as an ignored whistleblower complaint about those same practices. Both documents were previously requested and never produced.
“There is considerable reason to believe that ActBlue may have deliberately withheld this responsive material to impede our investigation,”
the committee chairs wrote Tuesday.
Fundraising Through the Fire
If ActBlue’s leadership is concerned about the investigation, it has a peculiar way of showing it. The organization announced on the same day as the congressional letter that it raised a record $568 million in the first quarter of 2026 — a 50 percent increase over the same period in the 2022 midterms. That includes $391 million directed toward federal candidates, even as the DOJ and three House committees are probing whether the very infrastructure channeling those funds has been compromised by illegal foreign money.
One is tempted to ask whether the organization’s boast of record fundraising is confidence — or defiance. ActBlue’s chief technology officer, Jason Wong, published a blog post the same day asserting that the platform’s “engineering team has built robust safeguards into every layer of the platform.” That is almost word-for-word the same assurance the company’s CEO gave Congress in 2023 — the very assurance its own lawyers privately said was inaccurate.
The Larger Question No One in the Media Is Asking
ActBlue processed more than $3.8 billion in contributions during the 2024 presidential election cycle. Even if — as the organization’s board member Kimberly Peeler-Allen insists — less than one percent of transactions showed signs of foreign origin, that figure represents nearly $38 million in potentially illegal contributions flowing into American elections. That is not a rounding error. That is a number that should make every American, regardless of party, demand a full accounting.
Federal law is unambiguous on this point: foreign nationals and non-permanent residents are prohibited from contributing to federal candidates or political action committees. The concern is not abstract. It strikes at the bedrock principle that American elections belong to Americans. Scripture affirms what common sense already tells us — that those entrusted with power over others bear a solemn obligation to exercise it honestly. As the Apostle Paul wrote to the Romans, “Let every soul be subject unto the higher powers” — a command that runs in both directions, requiring not only citizens to obey the law, but institutions wielding civic power to operate within it.
The self-styled champions of “democracy” who populate ActBlue’s leadership and donor base have long treated any Republican scrutiny of election integrity as tantamount to authoritarianism. The irony is almost too rich to catalogue: the same party that spent years insisting that foreign interference is an existential threat to democracy apparently built its primary fundraising engine on a system that its own attorneys believed was permitting exactly that — and then told Congress otherwise.
What Comes Next
With a two-week deadline now formally on the record, ActBlue faces a choice between compliance and contempt. Given the organization’s track record of subpoena-dodging since Republicans first began requesting documents in 2023, there is little reason for optimism that they will suddenly embrace transparency. The committee chairmen have made clear they are prepared to escalate. The DOJ and FBI are separately conducting their own investigations, and the clock on the Trump administration’s demand for a formal report on ActBlue’s practices has long since run.
What ActBlue cannot do is spend its way out of a congressional subpoena, no matter how many millions it raises in a quarter. The question is whether Washington’s oversight machinery will prove equal to the task of holding one of the most powerful institutions in Democratic politics accountable — or whether the investigation will quietly fade as so many others have before it. Based on the seriousness with which Steil, Jordan, and Comer appear to be approaching this, that quiet fade seems less likely than it once did.
Preparing for the Unexpected: Your Essential Partner in Health Readiness
In an increasingly unpredictable world—where supply chain disruptions, natural disasters, and global travel can leave us vulnerable to sudden health challenges—being prepared isn’t just smart; it’s essential.
That’s where Jase Medical steps in, offering innovative solutions that empower individuals and families to take control of their health with emergency medication kits designed for real-life scenarios. As someone who’s always advocated for proactive wellness, I was impressed by how Jase Medical combines expert medical guidance with convenient, customizable options to ensure you’re never caught off guard.
At the heart of their offerings is the Jase Case, a comprehensive emergency antibiotic kit priced at just $289.95. This powerhouse contains five life-saving antibiotics and five vital symptom-relief medications, capable of treating over 50 common infections—from respiratory issues and skin conditions to traveler’s diarrhea and more.
What sets it apart? It’s fully customizable with 28 add-on options, including a specialized KidCase for children ages 2-11, making it ideal for families.
Whether you’re stocking up for home emergencies or preparing for remote adventures, the Jase Case provides peace of mind with medications that boast extended shelf lives—up to five years or longer when stored properly, with studies showing 90% potency retention even after 20 years.
For those on the move, the Jase Go travel med kit at $129.95 is a game-changer. Curated by physicians, it addresses over 30 common travel ailments, from digestive upsets to minor injuries, ensuring explorers, hikers, and globetrotters can handle health hiccups without derailing their plans.
And for targeted concerns, Jase Medical offers specialized kits like the UTI Kit ($99.95), which includes test strips and treatments for urinary tract infections, vaginal candidiasis, and even jock itch, or the Parasites Kit (starting at $199.95), featuring compounded Ivermectin and Mebendazole to combat internal and external parasitic infections.
But Jase Medical isn’t just about one-off kits; their Jase Daily service provides an extended supply of your ongoing prescriptions, supporting hundreds of medications for chronic conditions like diabetes, heart health, high blood pressure, mental health, and more. This ensures long-term preparedness, safeguarding against factory shutdowns or extreme weather that could interrupt your regular supply.
The process couldn’t be simpler or more reassuring. Start by customizing your order online, then benefit from a thorough review by a team of world-class physicians who ensure safety and accuracy. In most cases, prescriptions are issued after a quick consultation—sometimes just a call to clarify allergies or needs—and your kit arrives discreetly at your door. While they don’t accept traditional health insurance, many customers use HSA cards, and refills are available for added convenience.
What truly stands out is the real-world impact. As radio host Glenn Beck puts it, “The supply lines for antibiotics already are stressed to the max. Please have some antibiotics on hand… You can do it through Jase.”
One satisfied customer shared, “It could have been a nightmare. Instead, the best trip we’ve had,” after their kit turned a potential health crisis into a minor blip during a family vacation.
In a time when health uncertainties loom larger than ever, Jase Medical isn’t just selling products—it’s delivering empowerment. Don’t wait for the next disruption; visit Patriot.TV/meds today to build your personalized emergency plan and step into a more secure tomorrow. Your health, and your family’s, deserves nothing less.








